Position in DNLI
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$42,720
+$36,941 QoQ
Shares Held
1,661
+451.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#211
of 290 holders
Holding Since
Jun 2024
7 quarters on record
Voting authority
Sole 89%
Shared 0%
None 11%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Arax Advisory Partners holds $59,653,938 across 287 Biotechnology names. DNLI ranks #107 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
118,402 | $13,422,050 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,563 | $5,962,913 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
13,844 | $4,167,459 | |
| 4 | EXEL |
Exelixis, Inc.
|
70,160 | $3,817,405 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
66,469 | $2,592,955 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,662 | $2,315,755 | |
| 7 | MESO |
Mesoblast Ltd
|
168,022 | $2,273,337 | |
| 8 | FTRE |
Fortrea Holdings Inc.
|
88,116 | $1,533,218 |
All Filings in DNLI
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $42,720 | 1,661 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $5,779 | 301 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $3,268 | 198 | Shares | Sole | 2026-02-13 | |
| 2025-06-30 | $727 | 52 | Shares | Sole | 2025-08-12 | |
| 2024-12-31 | $2,384 | 117 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $3,408 | 117 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $2,716 | 117 | Shares | Sole | 2024-08-06 | |
| No filing history on record for this holder in this stock. | ||||||